MOLN · Molecular Partners AG · Metrics
Market Cap
$160.88M
Shares
38.31M
MOLN metrics
52 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$4.18
Market cap
$160.88M
Price action
20 metricsPrice change (1W)
-3.9%
Price change (30D)
-0.7%
Price change (3M)
+12.7%
Price change (6M)
-11.3%
Price change (YTD)
-4.1%
Price change (1Y)
+8.6%
Trailing year
Price change (5Y)
-78.6%
52-week high
$5.13
52-week low
$3.54
Change from 52-week high
-18.4%
Change from 52-week low
+18.1%
Annualized volatility
55.5%
Annualized volatility (3M)
—
Beta
0.5
RSI (14D)
48.2
Price vs SMA 50
+2.3%
Price vs SMA 200
-1.1%
Avg volume (3M)
4,893
Relative volume
0.2
Average dollar volume
$19,481
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
38.31M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.2
reciprocal yield 45.0%
FCF yield
-36.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-40.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-01-10
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$51.70M
Net income (TTM)
−$64.52M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-87.4%
Return on assets
-67.6%
Debt / equity
—
Current ratio
7.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$58.37M
Quick ratio
7.3
Interest coverage
-118.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$84.05M
Total assets
$93.66M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$58.13M
Capital expenditures (TTM)
$239,498
R&D (TTM)
$46.16M
SG&A (TTM)
—
Stock compensation (TTM)
$4.91M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
5
13F filer change QoQ
+1
Institutional ownership
9.4%
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
40 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—